drugset / Trial / NCT01264731
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine 1) the safety of administration of topical 5% imiquimod cream with or without administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma and 2) evaluate whether topical imiquimod at sites of melanoma metastasis, with or without vaccine, increases a) endothelial expression of E-selectin and b) T cell infiltration.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Imiquimod | Other / unclassified | 5 % | Topical |
| Comparator | Imiquimod | Other / unclassified | 250 mg | Topical |
| Comparator | MELITAC 12.1 | Vaccine | 100 ug | Subcutaneous |
| Comparator | MELITAC 12.1 | Vaccine | 200 ug | Subcutaneous |